Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FE 204205 in Cirrhotic Portal Hypertension
NCT02929407Phase 1Terminated
- Sponsor
- Ferring Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FE 204205 in Portal Hypertension (PH) (3 arms), sponsored by Ferring Pharmaceuticals. Primary endpoints: Change in Hepatic Venous Pressure Gradient at 2 hours, Type, Frequency and Intensity of Adverse Events at Day 14 and 10 more. Started Nov 2016; status: terminated.
02
Drugs
FE 204205
03
Conditions
Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT02929407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02929407.